Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 8	JAN 29	PHAR reloaded with new search and display fields
NEWS 9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13	FEB 26	MEDLINE reloaded with enhancements
NEWS 14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19	MAR 16	CASREACT coverage extended
NEWS 20	MAR 20	MARPAT now updated daily
NEWS 21	MAR 22	LWPI reloaded
NEWS 22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 23	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 24	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 26	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 27	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 28	MAY 01	New CAS web site launched
NEWS 29	MAY 08	CA/CAplus Indian patent publication number format defined

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:03:29 ON 14 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 09:03:39 ON 14 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6
DICTIONARY FILE UPDATES: 13 MAY 2007 HIGHEST RN 934672-05-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575839.str



chain nodes :
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
ring nodes :
1 2 3 4 5 6 7 8
ring/chain nodes :
26 27 28
chain bonds :
1-11 1-12 2-22 2-23 3-24 4-10 5-25 6-20 6-21 7-16 7-17 8-18 8-19 12-13
12-14 12-15 13-26 13-27 13-28
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 13-26 13-27 13-28
exact bonds :
1-11 1-12 2-22 2-23 3-8 3-24 5-7 5-25 6-20 6-21 7-8 7-16 7-17 8-18
8-19 12-13 12-14 12-15
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS

L1 STRUCTURE UPLOADED

L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10575839.str



chain nodes :
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
ring nodes :
1 2 3 4 5 6 7 8
ring/chain nodes :
26 27 28
chain bonds :
1-11 1-12 2-22 2-23 3-24 4-10 5-25 6-20 6-21 7-16 7-17 8-18 8-19 12-13
12-14 12-15 13-26 13-27 13-28
ring bonds :
1-2 1-6 2-3 3-4 3-8 4-5 5-6 5-7 7-8
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-10 5-6 13-26 13-27 13-28
exact bonds :
1-11 1-12 2-22 2-23 3-8 3-24 5-7 5-25 6-20 6-21 7-8 7-16 7-17 8-18
8-19 12-13 12-14 12-15
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 10:CLASS 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS

```
L2      STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l2
SAMPLE SEARCH INITIATED 09:05:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    10288 TO ITERATE

 19.4% PROCESSED     2000 ITERATIONS                                 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       199682 TO   211838
PROJECTED ANSWERS:               1 TO      238

L3            1 SEA SSS SAM L2

=> s l2 full
FULL SEARCH INITIATED 09:05:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   205421 TO ITERATE

100.0% PROCESSED   205421 ITERATIONS                             211 ANSWERS
SEARCH TIME: 00.00.01

L4          211 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                             173.00     173.21

FILE 'CAPLUS' ENTERED AT 09:05:21 ON 14 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 May 2007  VOL 146 ISS 21
FILE LAST UPDATED: 13 May 2007  (20070513/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
```

=> s l4 full
L5 11 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:146107 CAPLUS
DOCUMENT NUMBER: 146:229203
TITLE: Preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists.
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016639	A2	20070208	WO 2006-US30153	20060802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-704579P P 20050802
OTHER SOURCE(S): MARPAT 146:229203
GI



I

AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH2, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; R3 = H, OH; X = physiol. acceptable anion], were prepared for treatment of chronic obstructive pulmonary disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, 2-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-1,1-bis(2-methyl-2-thienyl)ethanol (preparation given) was treated with MeBr in tert-Bu Me ether to give 61% (3-endo)-3-[2-hydroxy-2,2-bis(3-methyl-2-thienyl)ethyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide.
IT 924646-68-4P 924646-70-8P 924646-72-0P

924646-74-2P 924646-76-4P 924646-78-6P
924655-67-4P 924655-70-9P 924655-72-1P
924655-73-2P 924655-75-4P 924655-77-6P
924655-78-7P 924655-80-1P 924655-81-2P
924655-82-3P 924655-83-4P 924655-84-5P
924655-85-6P 924655-89-0P 924655-90-3P
924655-91-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-68-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924646-72-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-74-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-76-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-78-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-67-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-70-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-72-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-73-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-75-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-77-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-78-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-80-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-81-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-82-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924655-83-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-84-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-85-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-89-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-90-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924655-91-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

IT 924646-55-9P 924646-57-1P 924646-59-3P
924646-61-7P 924646-63-9P 924646-65-1P
924646-67-3P 924646-69-5P 924646-71-9P

924646-73-1P 924646-75-3P 924646-77-5P
924646-79-7P 924646-80-0P 924646-81-1P
924646-82-2P 924646-88-8P 924655-99-2P
924656-01-9P 924656-03-1P 924656-05-3P
924656-25-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-55-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-57-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3,4-difluorophenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-59-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3,5-difluorophenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-61-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-63-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3-fluoro-2-methylphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-65-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(5-fluoro-2-methylphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-67-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-69-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3-methoxyphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-71-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-73-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-75-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-77-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis[5-(difluoromethyl)-2-thienyl]-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-79-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-80-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-81-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-88-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924655-99-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924656-01-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924656-03-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis[(2-fluorophenyl)methyl]-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924656-05-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924656-25-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:144089 CAPLUS
DOCUMENT NUMBER: 146:229182
TITLE: Preparation of 3-(arylethenyl)-8,8-dimethyl-8-azoniabicyclo[3.3.1]octanes as M3 muscarinic acetylcholine receptor antagonists.
INVENTOR(S): Busch-Petersen, Jakob; Laine, Dramane Ibrahim; Palovich, Michael R.; Davis, Roderick S.; Fu, Wei; Xie, Haibo
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 35pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007016650	A2	20070208	WO 2006-US30218	20060802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, [illegible] RG, RZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-704578P P 20050802
OTHER SOURCE(S): MARPAT 146:229182

GI



I

AB Title compds. [I; R1, R2 = (substituted) Ph, thienyl, pyridyl, PhCH2, pyrimidinyl, thiazolyl, isothiazolyl, cycloalkyl, etc.; X = pharmaceutically acceptable counterion], were prepared for treatment of COPD, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, emphysema, and allergic rhinitis (no data). Thus, (endo)-3-[2,2-bis(3-hydroxyphenyl)ethenyl]-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide was prepared from tri-Me phosphonoacetate, tropinone, MeI, and 3-methoxyphenylmagnesium bromide.

IT 924646-91-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic acetylcholine receptor antagonists)

RN 924646-91-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



IT 924646-55-9P 924646-57-1P 924646-59-3P
924646-61-7P 924646-63-9P 924646-65-1P
924646-67-3P 924646-68-4P 924646-69-5P
924646-70-8P 924646-71-9P 924646-72-0P
924646-73-1P 924646-74-2P 924646-75-3P
924646-76-4P 924646-77-5P 924646-78-6P
924646-79-7P 924646-80-0P 924646-81-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylethenyldimethylazoniabicyclooctanes as M3 muscarinic

acetylcholine receptor antagonists)

RN 924646-55-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-57-1 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3,4-difluorophenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-59-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3,5-difluorophenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-61-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-63-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3-fluoro-2-methylphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-65-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(5-fluoro-2-methylphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-67-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-68-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-69-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(3-methoxyphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-70-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● I^-

RN 924646-71-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-72-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-73-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-74-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-75-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-76-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-77-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis[5-(difluoromethyl)-2-thienyl]-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



RN 924646-78-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



● Br^-

RN 924646-79-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-80-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-81-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-88-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.



RN 924646-89-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-bis(2-methoxyphenyl)-8-methyl-, (3-exo)- (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:451115 CAPLUS
DOCUMENT NUMBER: 143:7605
TITLE: A preparation of azabicyclo[3.2.1]octane derivatives, useful as M3 muscarinic acetylcholine receptor antagonists
INVENTOR(S): Wan, Zehong; Yan, Hongxing; Palovich, Michael R.; Laine, Dramane I.; Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; [illegible]
PATENT ASSIGNEE(S): GlaxoSmithKline Limited, UK
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046586	A2	20050526	WO 2004-US36663	20041104
WO 2005046586	A3	20050728		
WO 2005046586	A8	20050901		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682142	A2	20060726	EP 2004-810294	20041104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
JP 2007510731	T	20070426	JP 2006-539633	20041104
PRIORITY APPLN. INFO.:			US 2003-517243P P	20031104
			WO 2004-US36663 W	20041104

OTHER SOURCE(S): CASREACT 143:7605; MARPAT 143:7605
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a preparation of azabicyclo[3.2.1]octane derivs. of formula I•X- [wherein: X- is an anion; R1 is alkyl, alkenyl, alkylcycloalkyl, or alkyl-OMe, etc.; R2 is (cyclo)alkyl, heterocycloalkyl, or cycloalkylalkyl, etc.], useful as M3 muscarinic acetylcholine receptor antagonists (no biol. data). For instance, quaternary azabicyclo[3.2.1]octane derivative II•Br- was prepared via quaternization of N-methylazabicyclo[3.2.1]octane derivative III by cyclopropylmethyl bromide with a yield of 51%.

IT 852436-01-2P 852436-02-3P 852460-99-2P
852461-00-8P 852461-01-9P 852461-02-0P
852461-03-1P 852461-04-2P 852461-05-3P
852461-06-4P 852461-07-5P 852461-08-6P
852461-09-7P 852461-10-0P 852461-11-1P
852461-12-2P 852461-13-3P 852461-14-4P
852461-18-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azabicyclo[3.2.1]octane derivs. useful as M3 muscarinic acetylcholine receptor antagonists)

RN 852436-01-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-[2-(phenylmethoxy)ethyl]-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relevance pharmaceuticals



● Br^-

RN 852436-02-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(3-phenoxypropyl)-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852460-99-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(5-hexenyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-00-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(3-phenylpropyl)-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-01-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(cyclohexylmethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-02-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(cyclopropylmethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN [illegible]
CN 8-Azoniabicyclo[3.2.1]octane, 8-butyl-3-(2-cyano-2,2-diphenylethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-04-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 8-(4-chlorobutyl)-3-(2-cyano-2,2-diphenylethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-05-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-dodecyl-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-06-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(2-

Relative stereochemistry.



● I^-

RN 852461-07-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(phenylmethyl)-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-08-6 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(2-hydroxyethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-09-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-ethyl-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-10-0 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-propyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-11-1 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(2-cyclohexylethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-12-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(2-cyanopropyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-13-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-(2-methoxyethyl)-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-14-4 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-[2-(2-methoxyethoxy)ethyl]-8-methyl-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 852461-18-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8-methyl-8-(4,4,4-trifluorobutyl)-, bromide, (3-endo,8-syn)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 850607-53-3P 852435-95-1P 852435-97-3P
852435-98-4P 852435-99-5P 852436-00-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azabicyclo[3.2.1]octane derivs. useful as M3 muscarinic acetylcholine receptor antagonists)
RN 850607-53-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, 8-methyl-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852435-95-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, α,α-diphenyl-8-(phenylmethyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852435-97-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, 8-(5-hexenyl)-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852435-98-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, α,α-diphenyl-8-[2-(phenylmethoxy)ethyl]-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852435-99-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, α,α-diphenyl-8-(3-phenylpropyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 852436-00-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, 8-(3-phenoxypropyl)-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:369284 CAPLUS
DOCUMENT NUMBER: 142:423894
TITLE: 8-Methyl-8-azabicyclo[3.2.1]octane derivative muscarinic acetylcholine receptor antagonists, their preparation, and their therapeutic use
INVENTOR(S): Busch-Petersen, Jakob; Palovich, Michael R.; Wan, Zehong; Yan, Hongxing; Zhu, Chongjie
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037280	A1	20050428	WO 2004-US33638	20041012
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004281724	A1	20050428	AU 2004-281724		20041012
CA 2542657	A1	20050428	CA 2004-2542657		20041012
EP 1677795	A1	20060712	EP 2004-794886		20041012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004015361	A	20061212	BR 2004-15361		20041012
CN 1893948	A	20070110	CN 2004-80037266		20041012
JP 2007508390	T	20070405	JP 2006-535591		20041012
US 2007105895	A1	20070510	US 2006-575839		20060413
NO 2006002042	A	20060508	NO 2006-2042		20060508
PRIORITY APPLN. INFO.:			US 2003-511009P	P	20031014
			WO 2004-US33638	W	20041012

OTHER SOURCE(S): MARPAT 142:423894

AB 8-Methyl-8-azabicyclo[3.2.1]octane derivative muscarinic acetylcholine receptor antagonists are provided. Compound preparation is included. Compds. of the invention may be used to treat muscarinic acetylcholine receptor-mediated diseases.

IT 850607-53-3P 850607-55-5P 850607-65-7P 850607-66-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(azabicyclooctane derivative muscarinic acetylcholine receptor antagonists, preparation, and therapeutic use)

RN 850607-53-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, 8-methyl-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-55-5 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanamide, 8-methyl-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-65-7 CAPLUS
CN Benzamide, N-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-66-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanenitrile, 8-methyl-α,α-di-2-thienyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 850607-52-2P 850607-54-4P 850607-56-6P
850607-57-7P 850607-58-8P 850607-59-9P
850607-60-2P 850607-61-3P 850607-62-4P
850607-63-5P 850607-64-6P 850607-67-9P
850607-68-0P 850607-69-1P 850607-70-4P
850607-71-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(azabicyclooctane derivative muscarinic acetylcholine receptor antagonists, preparation, and therapeutic use)

RN 850607-52-2 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-methoxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, iodide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 850607-54-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 8-methyl-3-(2,2,2-triphenylethyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-56-6 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanoic acid, 8-methyl-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-57-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-, iodide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 850607-58-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 850607-59-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanol, 8-methyl-β,β-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-60-2 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-propanamide, 8-methyl-α,α-diphenyl-N-(phenylmethyl)-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-61-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(3-amino-3-oxo-2,2-diphenylpropyl)-8,8-dimethyl-, iodide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-62-4 CAPLUS
CN Urea, N-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-63-5 CAPLUS
CN Urea, N-ethyl-N'-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-64-6 CAPLUS
CN Acetamide, N-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-67-9 CAPLUS

CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyano-2,2-di-2-thienylethyl)-8,8-dimethyl-, iodide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● I^-

RN 850607-68-0 CAPLUS
CN Benzenesulfonamide, N-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-69-1 CAPLUS
CN Urea, [3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-70-4 CAPLUS
CN Methanesulfonamide, N-[3-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-2,2-diphenylpropyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 850607-71-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[3-(benzoylamino)-2,2-diphenylpropyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

IT 101781-55-9 850607-73-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(azabicyclooctane derivative muscarinic acetylcholine receptor antagonists, preparation, and therapeutic use)
RN 101781-55-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α,α-di-2-thienyl- (9CI) (CA INDEX NAME)



RN 850607-73-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α,α-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 850607-74-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(azabicyclooctane derivative muscarinic acetylcholine receptor antagonists, preparation, and therapeutic use)

RN 850607-74-8 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-propanamine, 8-methyl-β,β-diphenyl-, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:99316 CAPLUS

DOCUMENT NUMBER: 142:183475

TITLE: Muscarinic acetylcholine receptor antagonists

INVENTOR(S): Belmonte, Kristen E.; Busch-Petersen, Jakob; Laine, Dramane; Palovich, Michael R.

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 19 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009362	A2	20050203	WO 2004-US23041	20040716
WO 2005009362	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259238	A1	20050203	AU 2004-259238	20040716
CA 2532433	A1	20050203	CA 2004-2532433	20040716
EP 1648461	A2	20060426	EP 2004-778509	20040716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1822839	A	20060823	CN 2004-80020652	20040716
BR 2004012537	A	20060919	BR 2004-12537	20040716
US 2006178396	A1	20060810	US 2006-565048	20060117
NO 2006000777	A	20060411	NO 2006-777	20060217
PRIORITY APPLN. INFO.:			US 2003-487982P	P 20030717
			WO 2004-US23041	W 20040716

OTHER SOURCE(S): MARPAT 142:183475

AB Muscarinic acetylcholine receptor antagonists, e.g., (3-endo)-3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide and

methods of using them are provided. In addition a pharmaceutical composition for
the treatment of muscarinic acetylcholinereceptor-mediated diseases comprising the above compound is disclosed.

IT 90114-71-9 102133-77-7 106655-98-5
106713-93-3 106954-22-7 834882-84-7
834882-85-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(muscarinic acetylcholine receptor antagonists)

RN 90114-71-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 102133-77-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106655-98-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106713-93-3 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106954-22-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 634662-64-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(3-cyclohexyl-2-hydroxy-2-phenylpropyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 834882-85-8 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, (3-endo)-, salt with 4-methylbenzenesulfonic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 805224-99-1
CMF C23 H30 N O

Relative stereochemistry.



CM 2

CRN 16722-51-3
CMF C7 H7 O3 S



L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:164586 CAPLUS
DOCUMENT NUMBER: 120:164586
TITLE: Synthesis of anticholinergics of 3-substituted tropane derivatives
AUTHOR(S): Wu, Peijin; Ran, Yunzhang; Wen, Guangling; Zhang, Qikai
CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Acad. Mil. Med. Sci., Beijing, 100850, Peop. Rep. China
SOURCE: Zhongguo Yaowu Huaxue Zazhi (1993), 3(1), 25-8
CODEN: ZYHZEF; ISSN: 1005-0108
DOCUMENT TYPE: Journal

LANGUAGE: Chinese
GI



I

AB Title compds. I (R, R1 = H, OH; RR1 = bond; R2 = 3-MeC6H4, 4-ClC6H4) were prepared starting from Et 3-tropanylacetate. I showed anticholinergic activity in mice.

IT 153307-14-3P 153307-15-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anticholinergic activity of)

RN 153307-14-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α-(3-methylphenyl)-α-phenyl- (9CI) (CA INDEX NAME)



RN 153307-15-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α-(4-chlorophenyl)-8-methyl-α-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1985:505186 CAPLUS

DOCUMENT NUMBER: 103:105186

TITLE: Studies on anticholinergics: synthesis of 3-substituted tropane derivatives

AUTHOR(S): Ran, Yunzhang; Wu, Peijin; Wen, Guangling; Zhang, Qikai

CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Acad. Milit. Med. Sci., Beijing, Peop. Rep. China

SOURCE: Yaoxue Xuebao (1984), 19(5), 361-6
CODEN: YHHPAL; ISSN: 0513-4870

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

GI



I



II

AB Tropanes I (R = H, R1 = OH, R2 = Ph, 2-MeC6H4, 4-MeC6H4, 4-MeOC6H4, 2-pyrrolyl, cyclopentyl, R3 = H, Ph, 2-MeC6H4, cyclopentyl; RR1 = bond, R2,R3 = same as above; R = R1 = H, R2,R3 = same as above) were prepared from 3-tropanone (II). Most of I showed anticholinergic activity in mice. Structure-activity relationships was discussed.

IT 98042-84-3P 98042-85-4P 98042-86-5P
98042-87-6P 98042-88-7P 98042-89-8P
98042-90-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, dehydration, and anticholinergic activity of)

RN 98042-84-3 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α-(2-methylphenyl)-α-phenyl- (9CI) (CA INDEX NAME)



RN 98042-85-4 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α-(4-methylphenyl)-α-phenyl- (9CI) (CA INDEX NAME)



RN 98042-86-5 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α-(4-methoxyphenyl)-8-methyl-α-phenyl- (9CI) (CA INDEX NAME)



RN 98042-87-6 CAPLUS

CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α-cyclopentyl-8-methyl-α-phenyl- (9CI) (CA INDEX NAME)



RN 98042-88-7 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α-phenyl-α-1H-pyrrol-2-yl- (9CI) (CA INDEX NAME)



RN 98042-89-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α,α-bis(2-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 98042-90-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-dicyclopentyl-8-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 98043-07-3P 98043-08-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, salt formation, and anticholinergic activity of)

RN 98043-07-3 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α,α-bis(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 98043-08-4 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, α,α-dicyclopentyl-8-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1963:27160 CAPLUS
DOCUMENT NUMBER: 58:27160
ORIGINAL REFERENCE NO.: 58:4510b-h
TITLE: 3-Substituted tropane derivatives. III. 3-Substituted tropane carbinols, alkenes, and alkanes
AUTHOR(S): Zirkle, Charles L.; Anderson, Elvin L.; Craig, Paul N.; Gerns, Fred R.; Indik, Zena K.; Pavloff, Alex M.
CORPORATE SOURCE: Smith, Kline, & French Labs., Philadelphia, PA
SOURCE: Journal of Medicinal & Pharmaceutical Chemistry (1962), 5, 341-56
CODEN: JMPCAS; ISSN: 0095-9065
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 58:27160
GI For diagram(s), see printed CA Issue.
AB cf. CA 57, 3389b. For testing as cholinolyti: agents, a series of 3-substituted tropane derivs. (Ia) were prepared by the following sequence: (X = 3α-, or 3β-tropinyl) X(CH2)nCO2Me → X(CH2)nCOR (I) → X(CH2)nC(OH)RR' (II) → X: CRR' (III), XCH:CRR' (IV), or XCH2CH:CRR' (V) → X(CH2)nCHRR' (VI) using the procedures followed by Adamson for open-chain analogs (Adamson, et al., CA 45, 8462f). Compds. prepared were (compound number, tropinyl group configuration, n, R, R', % yield, m.p., b.p./pressure, n25D, salts prepared with m.p. of each, and relative activity (atropine = 1) given): I, α, 0, 2-thienyl, --, 4.4, --, 142-3°/ 0.4, --, picrate 259°, --; I, α, 1, Ph, --, 75,--, 140-3°/0.2,--, HCl 140-3°, --; I, α, 1, cyclohexyl, --, 35, --, 142-4°/0.8, --, picrate 165-8°, MeBr 297-9°, --; I, α, 1, 2-cyclohexylethyl, --, 74, --, 157-64°/0.7, 1.5010, picrate 148-50°, --; I, α, 2, Et, --, 77, --, 105-9°/0.35, 1.4870, picrate 123.0-4.5°, --; II, β, O, Me, Me, 84, --, 116-19°/4, --, picrate [illegible] 2-thienyl, 8.0, 157.5-9.0°, --, --, --, --; II, α, O, Ph, Ph, 47, 185.5-6.0°, --, --, HCl 290°, citrate 112-18% picrate 214.0-15.5°, MeBr 309-10°, citrate 0.001, MeBr salt 0.1; II,

β, O, Ph, Ph, 86, 182-4°,--,--, HCl 325°, picrate
230-1°, HCl salt 0.001; II, α, 1, Ph, Ph, 76, 147-8°,
--, --, HCl 235°, HBr 230°, MeBr 282°, HCl salt 1,
MeBr salt 0.1-1.0; II, β, 1, Ph, Ph, --, 178-9°, --, --, HCl
253.5°, HCl salt 0.001; II, α, 1, cyclohexyl, Ph, 90,
139.0-40.5°,--,--, HCl 254-5°, MeBr 262°, HCl salt
0.1; II, α, 1, 2-cyclohexylethyl, Ph, above 66, 104-6°,--,--,
HCl 215-16°, citrate 134-6°, MeBr 263-5°, HCl salt
0.01; II, α, 1, Ph, Et, 12, --, --, --, HCl 237°, HCl salt
0.01-0.10; II, α, 1, 2-pyridyl, Ph, 64, 117.5-18.5°, --, --,
HI 194-6°, dipicrate 191-2°, MeBr 268°, HI salt 0.01;
II, α, 1, Ph, 2-thienyl, 73, 137.5-9.0°,--,--, maleate
145-6°, MeBr 256°, maleate 1; II, α, 1,2-thienyl,
2-thienyl, 69, 138-40°, --, --, HOAc 189-90°, MeBr
245.5°, HOAc salt 1; II, α, 2, Ph, Ph, 92, 142-3°, --,
--, HCl 249-50°, MeBr 299°, HCl salt 0.01, MeBr salt 0.1;
III, --, --, Ph, Ph,--,--,--,--,HCl 275-8°, picrate 237-8°,
MeBr 281-5°, HCl salt 0.01, MeBr salt 0.1-1.0; III,--,--,
2-thienyl, 2-thienyl, 76 --,--,-- HCl 224-5°, --; IV, α, --,
Ph, Ph, 100, 111-12°, --, --, HCl 217-18°, picrate
186-8°, MeBr 286° HCl salt 1-10, MeBr salt 0.1-1.0; IV,
α --, cyclohexyl, Ph, 95,--,--,--, HCl 195-6°, HI
222.5-4.0°, MeBr 250-5° HCl salt 1; IV, α, --, Ph,
Et,--,--,--,--, HCl 214-15°, --; IV, α, --, Ph, 2-pyridyl,
78, 97.5-9.5, --, -- tartrate 165-7°, picrate 204-6°, MeBr
227-8°, --; IV, α, --, Ph, 2-thienyl, 96, 65-70, --, --, HCl
194-200° tartrate 174-5° picrate 209-10°, MeBr
258-9°, tartrate 0.1-1.0; IV, α, --, 2-thienyl, 2-thienyl,
76,--,--,--, HCl 230-2°,picrate 190-2°, MeBr 252-3°,
HCl salt 1; V, α, --, Ph, Ph, --,--,--, citrate 174°, MeBr
280°, citrate 0.001, MeBr salt 0.01; VI, α, O, Me, Me, -- --,
109-11°/29, 1.4739, HCl 194- 6% MeI 224-6°,--; VI, α,
O, Ph, Ph,--, 70-2°,--,--, HCl above 310°, MeBr
277-8°, HCl 0.01, MeBr salt 0.1; VI, α, 1,Ph, Ph,--,--,--,--,
HCl 244-5°, MeBr 257-8° HCl salt 1-10, MeBr 1; VI, α,
1, cyclohexyl, Ph,--,--,--,--, HCl 167.0-8.5°, citrate
153-5°, picrate 140-1°, MeBr 259-60°, citrate
0.1-1.0; VI, α, 1, 2-cyclohexylethyl, Ph,--,--,--,--, HCl
198-200°. --; VI, α, 1, Ph, 2-pyridyl,--,--,--,--, tartrate
78-80°picrate 201-3°, --; and VI, α, 2, Ph,
Ph,--,--,--,--, citrate 170°, MeBr 277°, citrate
0.001-0.010, MeBr salt 0.01.

IT 88781-37-7P, 3α-Tropaneethanol, α-ethyl-α-phenyl-
, hydrochloride 90114-71-9P, 8-Azoniabicyclo[3.2.1]octane,
3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide
95131-86-5P, 3α-Tropaneethanol, α,α-diphenyl-
100167-89-3P, 3α-Tropaneethanol, α,α-di-2-
thienyl- 102133-77-7P, 8-Azoniabicyclo[3.2.1]octane,
3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide
104038-18-8P, 3α-Tropaneethanol, α-cyclohexyl-α-
phenyl- 104038-19-9P, 3α-Tropaneethanol,
α-cyclohexyl-α-phenyl-, hydrochloride 106172-79-6P,
3α-Tropaneethanol, α,α-di-2-thienyl-, acetate
106302-20-9P, 3α-Tropaneethanol, α-phenyl-α-2-
thienyl- 106655-98-5P, 8-Azoniabicyclo[3.2.1]octane,
3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide
106954-22-7P, 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-
2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide 107136-74-3P,
3α-Tropaneethanol, α-(2-ethylcyclohexyl)-α-phenyl-,
hydrochloride 107136-75-4P, 3α-Tropaneethanol,
α-(2-ethylcyclohexyl)-α-phenyl- 107157-11-9P,
3α-Tropaneethanol, α-phenyl-α-2-thienyl-, maleate
107307-44-8P, 3α-Tropaneethanol, α-phenyl-α-2-

pyridyl- 107307-45-9P, 3α-Tropaneethanol, α-phenyl-α-2-pyridyl-, dipicrate 107422-64-0P, 3α-Tropaneethanol, α-phenyl-α-2-pyridyl-, hydriodide 888716-34-5P, 3β-Tropaneethanol, α,α-diphenyl-, hydrochloride 888716-35-6P, 3β-Tropaneethanol, α,α-diphenyl-
RL: PREP (Preparation)
(preparation of)

RN 88781-37-7 CAPLUS
CN 3α-Tropaneethanol, α-ethyl-α-phenyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 90114-71-9 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 95131-86-5 CAPLUS
CN 3-Tropaneethanol, α,α-diphenyl- (6CI, 7CI) (CA INDEX NAME)



RN 100167-89-3 CAPLUS
CN 3α-Tropaneethanol, α,α-di-2-thienyl- (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 102133-77-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-thienyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 104038-18-8 CAPLUS
CN 3α-Tropaneethanol, α-cyclohexyl-α-phenyl- (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 104038-19-9 CAPLUS
CN 3α-Tropaneethanol, α-cyclohexyl-α-phenyl-, hydrochloride (7CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 106172-79-6 CAPLUS
CN 3α-Tropaneethanol, α,α-di-2-thienyl-, acetate (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106302-20-9 CAPLUS
CN 3α-Tropaneethanol, α-phenyl-α-2-thienyl- (7CI) (CA INDEX NAME)

Relative stereochemistry.



RN 106655-98-5 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-(2-hydroxy-2,2-diphenylethyl)-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 106954-22-7 CAPLUS
CN 8-Azoniabicyclo[3.2.1]octane, 3-[2-hydroxy-2-phenyl-2-(2-pyridinyl)ethyl]-8,8-dimethyl-, bromide, (3-endo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● Br^-

RN 107136-74-3 CAPLUS
CN 3-Tropaneethanol, α-(2-ethylcyclohexyl)-α-phenyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 107136-75-4 CAPLUS
CN 3-Tropaneethanol, α-(2-ethylcyclohexyl)-α-phenyl- (7CI) (CA INDEX NAME)



RN 107157-11-9 CAPLUS
CN 3α-Tropaneethanol, α-phenyl-α-2-thienyl-, maleate (7CI) (CA INDEX NAME)

CM 1

CRN 102239-31-6
CMF C20 H25 N O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 107307-44-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α-phenyl-α-2-pyridinyl-, endo- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 107307-45-9 CAPLUS
CN 3α-Tropaneethanol, α-phenyl-α-2-pyridyl-, dipicrate (7CI) (CA INDEX NAME)

CM 1

CRN 107307-44-8

CMF C21 H26 N2 O

Relative stereochemistry.



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 107422-64-0 CAPLUS
CN 3α-Tropaneethanol, α-phenyl-α-2-pyridyl-, hydriodide (7CI) (CA INDEX NAME)

Relative stereochemistry.



●x HI

RN 888716-34-5 CAPLUS
CN 3β-Tropaneethanol, α,α-diphenyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 888716-35-6 CAPLUS
CN 3β-Tropaneethanol, α,α-diphenyl- (7CI) (CA INDEX NAME)



L5 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1958:93024 CAPLUS
DOCUMENT NUMBER: 52:93024
ORIGINAL REFERENCE NO.: 52:16402b-f
TITLE: 8-Alkylnortropane derivatives
INVENTOR(S): Zirkle, Charles L.
PATENT ASSIGNEE(S): Smith, Kline & French Laboratories
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2800482		19570723	US 1955-519650	19550701

AB 3-Benzhydrylidenetropane picrate m. 237-8° (aqueous alc.); methobromide, m. 281-5° (iso-PrOH-Me2CO); etho(ethyl sulfate), white solid. Di(2-thienyl)-3-tropanylcarbinol (0.5 g.) in CHCl3 treated with dry HCl until strongly acid gave 2-[di(2-thienyl)methylidene]tropane-HCl, m. 224-5° (alc. Et2O). 1,1-Di(2-thienyl)-3-tropaneethanol (1 g.), 2 g. (CO2H)2, and 3 ml. H2O refluxed 2 hrs. gave 1,1-di(2-thienyl)-2-(3-tropanyl)ethylene, m. 74-6° (ligroine); picrate, m. 190-2° (aqueous Me2CO); HCl salt, m. 230-2° (alc. Et2O); methobromide, m. 252-3°. 1,1-Diphenyl-2-(3-tropanyl)ethylene methobromide, m. 286° (alc.); maleate; metho-p-toluene-sulfonate, white solid. 1-Phenyl-1-(2-thienyl)-3-tropaneethanol (9.7 g.), 19.4 g. (CO2H)2, and 29 ml. H2O refluxed 2 hrs. and the mixture made alkaline gave 1-phenyl-1-(2-thienyl)-2-(3-tropanyl)ethylene, m. 69-72°; picrate, m. 209-10°; tartrate, m. 174-5° (alc.-Et2O); methobromide, m. 258-9° (alc.-Et2O). 1-Phenyl-1-(2-pyridyl)-2-(3-tropanyl) ethylene methobromide, m. 228-30° (alc.-Et2O); tartrate, m. 165-7° (alc.-Et2O). 1-(2-Cyclohexylethyl)-1-phenyl-3-tropaneethanol (1 g.) in 10 ml. AcOH and 3 ml. 37% HCl refluxed 0.5 hr. gave the dehydration product, λ 235 mμ, log ε 3.58. 1-Cyclohexyl-1-phenyl-2-(3-tropanyl) ethylene-HI, m. 222.5-4.0°; methobromide, m. 250-2° (W20); hydriodide, white solid. 1,1-Diphenyl-3-tropanepropanol (15 g.) in 50 ml. 37% HCl 1.5 hrs. at 100° gave 1,1-diphenyl-3-(3-tropane-1-propene, m. 59-60°, b0.4 170-3°; citrate, m. 174°. 1-(2-Pyridyl-1-p-tolyl-4-(3-

tropanyl)-1-butanol (0.5 g.) and 2 ml. 85% H_2SO_4 heated 15 min. at 155° gave 1-(2-pyridyl)-1-p-tolyl-4-(3-tropanyl)-1-butene. A similar dehydration of 1-cyclopentyl-1-phenyl-3-tropanebutanol with HCl gave the corresponding butene as the HCl salt; neutralization with NH_4OH gave the free base as a yellow oil.

IT 124145-26-2P, 8-Ethyl-3-(2-hydroxy-2,2-diphenylethyl)tropanium ethyl sulfate
RL: PREP (Preparation)
(preparation of)

RN 124145-26-2 CAPLUS

CN 8-Ethyl-3-(2-hydroxy-2,2-diphenylethyl)tropanium ethyl sulfate (6CI) (CA INDEX NAME)

CM 1

CRN 124145-25-1
CMF C24 H32 N O



CM 2

CRN 48028-76-8
CMF C2 H5 O4 S



L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1958:93023 CAPLUS
DOCUMENT NUMBER: 52:93023
ORIGINAL REFERENCE NO.: 52:16401g-i,16402a-b
TITLE: 8-Alkylnortropane derivatives
INVENTOR(S): Zirkle, Charles L.
PATENT ASSIGNEE(S): Smith, Kline & French Laboratories
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2800481		19570723	US 1955-519649	19550701

AB Me 3-tropanecarboxylate (10.1 g.) in 100 ml. Et_2O stirred 1.5 hrs. at room temperature with PhLi gave diphenyl-3-tropanylcarbinol, m. 214-15° (aqueous MeOH); citrate, m. 112-18° (iso-PrOH-Et_2O); methobromide, m. 309-10° (alc.). Et 3-tropaneacetate (I) (10 g.) in 20 ml. Et_2O refluxed with PhLi and 11.8 g. thiophene in Et_2O gave 1,1-di(2-thienyl 3-tropaneethanol, m. 138-40° (EtOAc); acetate, m. 189-90°; methobromide, m. 245.5° (alc.). 1,1-Diphenyl-3-tropaneethanol-HCl, m. 224.5° (ale.-Et_2O); methobromide, m. 282.2° (ale.-Et_2O)
I with concentrated HCl gave 3-tropaneacetic acid-HCl (II), m. 172-4°. II (11 g.) refluxed with PhLi gave Ph 3-tropanylmethyl ketone (III), b0.2 138-41°. III (9 g.) stirred several hrs. at room temperature with PhLi

gave 1,1-diphenyl-3-tropaneethanol-HBr, m. 230°. III (10 g.) treated with PhLi and thiophene gave 1-phenyl-1-(2-thienyl)-3-tropaneethanol, m. 137.5-9.0°; maleate, m. 145-6° (alc.-Et2O); methobromide, m. 256° (alc.). 1-Phenyl-1-(2-pyridyl)-3-tropaneethanol-HI, m. 194-6°; methobromide, m. 268° (alc.). 1-Ethyl-1-phenyl-3-tropaneethanol-HCl, m. 237-7.5° (alc.). 1-Cyclohexyl-1-phenyl-3-tropaneethanol-HCl, m. 254-5° (alc.-Et2O); methobromide, m. 262° (alc.-Et2O). 2-Cyclohexylethyl 3-tropanylmethyl ketone picrate, m. 148-50°; 1-(2-cyclohexylethyl)-1-phenyl-3-tropaneethanol-HCl, m. 215-16°; citrate, m. 134-6° (Me2CO-MeOH); methobromide, m. 263-5°. II (3.7 g.) treated with SOCl2 gave the acid chloride HCl salt which treated with CH2N2 gave the diazomethyl 3-tropanylmethyl ketone and subsequent treatment with Ag2O oxide gave Et 3-tropanepropionate (IV). IV (18 g.) treated with PhLi as above gave 1,1-diphenyl-3-tropanepropanol, m. 141-2.5°; HCl salt, m. 249-50°; methobromide salt, m. 299°. Cyclopentyl 3-(3-tropanyl)propyl ketone (6.6 g.) treated with PhLi as above gave 1-cyclopentyl-1-phenyl-3-tropanebutanol. Diphenyl-3-tropanecarbinol etho(ethyl sulfate) was a white solid. 1,1-Diphenyl-3-tropaneethanol metho-p-toluenesulfonate, m. 172-4°; etho(ethyl sulfate), m. 234-5°; butobromide, m. 225-7°; butiodide, m. 227-9°. 1-Cyclohexyl-1-phenyl-2-(3-tropane)ethanol butyl bromide was a white solid.

IT 102470-52-0, 3-Tropaneethanol, α-phenyl-α-2-pyridyl-
103034-31-7, 3-Tropaneethanol, α-(2-cyclohexylethyl)-α-phenyl-
(derivs.)

RN 102470-52-0 CAPLUS

CN 3-Tropaneethanol, α-phenyl-α-2-pyridyl- (6CI) (CA INDEX NAME)



RN 103034-31-7 CAPLUS

CN 3-Tropaneethanol, α-(2-cyclohexylethyl)-α-phenyl- (6CI) (CA INDEX NAME)



IT 88781-37-7P, 3-Tropaneethanol, α-ethyl-α-phenyl-, hydrochloride 95131-86-5P, 3-Tropaneethanol, α,α-diphenyl-, hydrohalides 101781-55-9P, 3-Tropaneethanol, α,α-di-2-thienyl- 102239-31-6P, 3-Tropaneethanol, α-phenyl-α-2-thienyl- 102239-71-4P, 3-Tropaneethanol, α,α-di-2-thienyl-, acetate 103757-37-5P, 3-Tropaneethanol, α-cyclohexyl-α-phenyl-, hydrochloride 107157-11-9P, 3-Tropaneethanol, α-phenyl-α-2-thienyl-, maleate 112717-86-9P, 3-(2-Hydroxy-2-phenylphenethyl)-8-methyltropanium bromide 113222-63-2P, 3-(2-hydroxy-2,2-di-2-thienylethyl)-8-methyltropanium bromide 114863-60-4P, 3-(β-Cyclohexyl-β-hydroxyphenethyl)-8-methyltropanium bromide 119016-27-2P,

3-(4-Cyclohexyl-2-hydroxy-2-phenylbutyl)-8-methyltropanium bromide 119640-59-4P, 8-Butyl-3-(β-cyclohexyl-β-hydroxyphenethyl)tropanium bromide 124145-26-2P, 8-Ethyl-3-(2-hydroxy-2,2-diphenylethyl)tropanium ethyl sulfate
RL: PREP (Preparation)
(preparation of)

RN 88781-37-7 CAPLUS
CN 3α-Tropaneethanol, α-ethyl-α-phenyl-, hydrochloride (7CI) (CA INDEX NAME)



● HCl

RN 95131-86-5 CAPLUS
CN 3-Tropaneethanol, α,α-diphenyl- (6CI, 7CI) (CA INDEX NAME)



RN 101781-55-9 CAPLUS
CN 8-Azabicyclo[3.2.1]octane-3-ethanol, 8-methyl-α,α-di-2-thienyl- (9CI) (CA INDEX NAME)



RN 102239-31-6 CAPLUS
CN 3-Tropaneethanol, α-phenyl-α-2-thienyl- (6CI) (CA INDEX NAME)



RN 102239-71-4 CAPLUS
CN 3-Tropaneethanol, α-[2-(dimethylamino)ethyl]-α-phenyl- (6CI) (CA INDEX NAME)



RN 103757-37-5 CAPLUS
CN 3-Tropaneethanol, α-cyclohexyl-α-phenyl-, hydrochloride (6CI) (CA INDEX NAME)



● HCl

RN 107157-11-9 CAPLUS
CN 3α-Tropaneethanol, α-phenyl-α-2-thienyl-, maleate (7CI) (CA INDEX NAME)

CM 1

CRN 102239-31-6
CMF C20 H25 N O S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 112717-86-9 CAPLUS
CN 3-(β-Hydroxy-β-2-thienylphenethyl)-8-methyltropanium bromide (6CI) (CA INDEX NAME)



● Br^-

RN 113222-63-2 CAPLUS
CN 3-(2-Hydroxy-2,2-di-2-thienylethyl)-8-methyltropanium bromide (6CI) (CA INDEX NAME)



● Br^-

RN 114863-60-4 CAPLUS
CN 3-(β-Cyclohexyl-β-hydroxyphenethyl)-8-methyltropanium bromide (6CI) (CA INDEX NAME)



● Br^-

RN 119016-27-2 CAPLUS
CN 3-(4-Cyclohexyl-2-hydroxy-2-phenylbutyl)-8-methyltropanium bromide (6CI) (CA INDEX NAME)



● Br^-

RN 119640-59-4 CAPLUS
CN 8-Butyl-3-(β-cyclohexyl-β-hydroxyphenethyl)tropanium bromide (6CI) (CA INDEX NAME)



● Br^-

RN 124145-26-2 CAPLUS
CN 8-Ethyl-3-(2-hydroxy-2,2-diphenylethyl)tropanium ethyl sulfate (6CI) (CA INDEX NAME)

CM 1

CRN 124145-25-1
CMF C24 H32 N O



CM 2

CRN 48028-76-8
CMF C2 H5 O4 S

$Et-O-SO_3^-$

L5 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1958:93020 CAPLUS
DOCUMENT NUMBER: 52:93020
ORIGINAL REFERENCE NO.: 52:16399b-i,16400a-i,16401a
TITLE: 8-Alkylnortropane derivatives
INVENTOR(S): Zirkle, Charles L.
PATENT ASSIGNEE(S): Smith, Kline & French Laboratories
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2800478		19570723	US 1955-519648	19550701

AB Some new physiologically active 3-substituted-8-alkylnortropanes, the nontoxic organic and inorg. salts, and the quaternary ammonium salts are

described. Me 3-(3-hydroxytropane)carboxylate (10 g.) in 50 ml. Ac2O heated 4 hrs. at 100°, the excess Ac2O and AcOH removed in vacuo, the residue poured into H2O, extracted with Et2O, and the Et2O evaporated gave Me 3-(3-acetoxytropane)-carboxylate (I), m. 66-7°, b15 162-5°. I (29 g.) added dropwise during 7 min. to a vertical tube heated to 420° and filled with pieces of Pyrex tubing, the apparatus swept with N, the product dissolved in dilute HCl, extracted with Et2O, the aqueous acid solution saturated with K2CO3, and the product separated gave Me 3-(2-tropene)carboxylate (II), b15 131-4°, n25.5D 1.4998. II (13 g.) in 100 ml. MeOH hydrogenated over 5 g. Raney Ni at 50 lb./sq. in. at room temperature and the mixture distilled gave Me 3-tropanecarboxylate (III), b18 128-32°, n25D 1.4819. III (10.1 g.) in 100 ml. Et2O stirred 1.5 hrs. at room temperature with a solution of PhLi (from 34.5 g. PhBr and 3.5 g. Li) in 100 ml. Et2O, the mixture added to 150 ml. H2O, and the solid collected and purified gave diphenyl-3-tropanecarbinol (IV), m. 185.5-6.0° (EtOAc). IV (5.6 g.) in 20 ml. AcOH and 25 ml. dilute HCl refluxed 10 min. and evaporated to dryness gave 3-benzhydrylidenetropane-HCl, m. 275-8° (alc.-Et2O); free base (V), a colorless oil. V (4 g.) in alc. hydrogenated over Raney Ni at 400 lb./sq. in. at 60° and the product chromatographed on Al2O3 gave 3-benzhydryltropane (VI), m. 70-2°. VI (1 g.) gave the HCl salt, unmelted below 310°; MeBr salt, m. 277-9°; etho(ethyl sulfate), white solid. Tropinone (13.9 g.), 11.3 g. NCCH2CO2Et, 1.6 g. NH4OAc, 7.3 g. AcOH, 20 ml. alc., and 0.6 g. Pd-C shaken under H at 50° and 60 lb./sq. in. gave Et α-cyano-3-tropaneacetate (VII), b0.3 116-18°, n24D 1.4942. VII (8 g.) in 30 ml. 37% HCl refluxed 13 hrs. and the crude 3-tropaneacetic acid-HCl esterified by leaving 3 days at room temperature in 50 ml. alc. with dry HCl gave Et 3-tropaneacetate (VIII), b2 104-5°, n25D 1.4774. VIII (42 g.) in 100 ml. Et2O similarly treated with PhLi gave 1,1-diphenyl-3-tropaneethanol (IX), m. 146.5-7.5° (EtOAc). IX (14.6 g.) in 29 ml. 37% HCl and 100 ml. AcOH refluxed 0.5 hr. gave 1,1-diphenyl-2-(3-tropanyl)ethylene (X), as the HCl salt, m. 217-18° (alc.-Et2O); free X, m. 109.5-10.0° (Me2CO). X (10 g.) in alc. hydrogenated over Raney Ni at 500 lb./sq. in. and 60° gave 1,1-diphenyl-2-(3-tropanyl)ethane, colorless oil; HCl salt, m. 244-5°; methobromide, m. 257-8° (alc.-Et2O); metho-p-toluenesulfonate, white solid; maleate, obtained by treating with maleic acid in alc. VIII in 37% HCl refluxed several hrs. gave 3-tropaneacetic acid-HCl (XI), m. 172-4° (MeOH-Et2O). XI (11 g.) similarly treated with PhLi followed by passage of HCl gave the HCl salt which when washed was reconverted to phenyl 3-tropanylmethyl ketone (XII), b0.2 138-41°. BuLi (from 3.7 g. BuCl and 0.7 g. Li) in 25 ml. Et2O treated slowly at -45° with 5.5 g. 2-bromopyridine in 10 ml. Et2O, the mixture stirred 10 min., and 2.5 g. XII in 30 ml. Et2O added slowly, the mixture stirred 15 min. at -15°, 50 ml. H2O added, the mixture stirred a further 15 min., a solid collected, the solid stirred with CHCl3 and H2O, and the CHCl3 layer removed, combined with the Et2O layer and evaporated gave 1-phenyl-1-(2-pyridyl)-3-tropaneethanol (XIII), m. 117-18.5° (EtOAc). XIII (1 g.) and 2 ml. 85% H2SO4 heated 15 min. at 155° and the solution made basic gave 1-phenyl-1-(2-pyridyl)-2-(3-tropanyl)ethylene (XIV), m. 97.5-9.5° (Me2CO). XIV 0.2 g.), 5 g. cyclohexene, and 0.3 g. 20% Pd-C refluxed 48 hrs. gave 1-phenyl-1-(2-pyridyl)-2-(3-tropanyl)ethane (XV) as a thick oil; picrate, m. 201-3° (aqueous Me2CO). XV also forms the tartrate, m. 78-80° (alc.-Et2O). XII (12.2 g.) in 50 ml. Et2O added slowly to PhMgBr solution (from 7.2 g. Mg) at 0°, the mixture stirred 1.5 hrs. at room temperature, then refluxed 1.5 hrs., decomposed with ice and 21 g. NH4Cl in 50 ml. H2O, the Et2O layer removed, and the aqueous phase extracted with CHCl3

gave 1-ethyl-1-phenyl-3-tropaneethanol (XVI), m. 119-20°. XVI (0.44 g.) was dehydrated by heating 40 min. at 100° with 3 ml. concentrated HCl to the ethylene, m. 170-200°. The ethylene hydrogenated in alc. over Raney Ni at 60° and 500 lb./sq. in. gave 1-ethyl-1-phenyl-2-(3-tropanyl)ethane (XVII), an oil, which formed an HCl salt. VIII (15 g.) similarly treated with 2-cyclohexylethylmagnesium bromide gave 2-cyclohexylethyl 3-tropanylmethyl ketone (XVIII), b0.7 157-64°, n24.5D 1.5010. XVIII (7.7 g.) in 20 ml. Et2O similarly treated with PhLi (from 9.5 g. PhBr) in Et2O at 0° gave 1-(2-cyclohexylethyl)-1-phenyl-3-tropaneethanol (XIX), m. 104-6° (EtOAc). XIX (0.5 g.), 1 ml. HI, 3 ml. AcOH, and 0.13 g. red P refluxed 3.5 hrs., the solution filtered, the filtrate diluted with H2O, the crude HI salt separated as an oil and crystallized gave 1-(2-cyclohexylethyl)-1-phenyl-2-(3-tropanyl)ethane-HI, m. 175° (alc.-Et2O). The free base was a colorless oil; HCl salt, m. 198-200°. Similarly, 25 g. VIII reacted with cyclohexylmagnesium bromide to give cyclohexyl 3-tropanylmethyl ketone (XX), b0.9-1.1 142-53°, crystallizing to a white solid on standing. XX (10 g.) similarly treated with PhLi gave 1-cyclohexyl-1-phenyl-3-tropaneethanol (XXI), m. 139-40.5° (EtOAc). XXI (1 g.) refluxed 0.5 hr. with AcOH and concentrated HCl gave the ethylene HCl salt, m. 195-6°. Hydrolysis gave the free base as an oil. The free base (4.4 g.) hydrogenated over Raney Ni at 500 lb./sq. in. and 60° gave 1-cyclohexyl-1-phenyl-2-(3 tropanyl)ethane, colorless oil; HCl salt, m. 167-8.5°; citrate, m. 153-5°; butiodide, white solid. N-Isopropylnortropanone (16.7 g.), 11.3 g. NCCH2CO2Et, 1.6 g. NH4OAc, 7.3 g. AcOH, 20 ml. alc., and 0.6 g. Pd-C shaken with H at 60 lb./sq. in. and 60°, the residue refluxed 12 hrs. with concentrated HCl gave crude 3-(N-isopropylnortropane)-acetic acid-HCl which was esterified with anhydrous MeOH and HCl 3 days at room temperature gave Me 3-(N-isopropylnortropane)acetate (XXII), b0.3 124-7°. XXII (11.3 g.) similarly treated with p-anisylmagnesium bromide gave p-anisyl 3-(N-isopropylnortropanyl)methyl ketone (XXIII), b0.2 160-4° and crystallized as a white solid. XXIII (7.5 g.) similarly treated with PhLi at 0° gave 1-(p-anisyl)-1-phenyl-3-(N-isopropylnortropane)ethanol (XXIV), white solid. Dehydration of XXIV with oxalic acid and H2O gave the ethylene, which when hydrogenated as described above gave 1-p-anisyl-1-phenyl-2-[3-(N-isopropylnortropanyl)]ethane; methobromide salt. VIII (164 g.) in 500 ml. Et2O refluxed 3 hrs. with 30 g. LiAlH4 in 2 l. Et2O gave 3-tropaneethanol (XXV), m. 63-4° (C6H6-ligroine). XXV (10 g.) in 50 ml. CHCl3 treated with 14.3 g. SOCl2, refluxed 45 min., and isolation gave 1-chloro-2-(3-tropanyl)ethane-HCl, m. 167-8° (alc.-Et2O); free base, b0.9 81°. The base (47 g.) and 0.1 g. NaI refluxed 17 hrs. with 49 g. KCN in 175 ml. alc. and 75 ml. H2O, NaOH added to the residual mixture, and the product isolated gave 3-tropanepropionitrile (XXVI), b0.3 114-16°, n25D 1.4958. XXVI (25 g.) in 100 ml. 37% HCl refluxed several hrs., and evaporated, the residue dissolved in 300 ml. alc., 5 ml. concentrated H2SO4 added, and the residue treated with 40% NaOH gave Et 3-tropanepropionate (XXVII), b0.4 97-100°, n25D 1.4770. Similarly XXVII treated with PhLi gave 1,1-diphenyl-3-tropanepropanol (XXVIII), m. 141-2.5°. Dehydration of XXVII with concentrated HCl and 40% NaOH added gave 1,1-diphenyl-3-(3-tropanyl)-1-propene (XXIX), b0.4 170-3°, m. 59-60°. XXIX (4.7 g.) hydrogenated over 5 g. Raney Ni gave 1,1-diphenyl-3-(3-tropanyl)propane as an oil; citrate, m. 170°; methobromide, m. 277°. XXVII reduced with 3 g. LiAlH4 gave 3-tropanepropanol (XXX), b2 128-31°. XXX (7.7 g.) treated with 10 g. SOCl2 gave the HCl salt, which treated with K2CO3 liberated 1-chloro-3-(3-tropanyl)propane (XXXI), b1 100-2°. XXXI (5 g.) refluxed 18 hrs. with 0.1 g. NaI, 5 g. KCN, 10 ml. alc., and 6 ml. H2O gave 3-tropanebutyronitrile (XXXII), b0.3 132-5°. XXXII (3 g.) refluxed several hrs. with concentrated HCl and the product treated with 40% NaOH gave Et 3-tropanebutyrate (XXXIII),

b0.5 115-19°. XXXIII (2.3 g.) similarly treated with p-tolyl magnesium bromide gave p-tolyl γ-(3-tropanyl)propyl ketone (XXXIV), b0.2 188-92°. XXXIV (1.5 g.) in 15 ml. Et2O treated with BuLi and 2-bromopyridine in Et2O gave 1-(2-pyridyl)-1-p-tolyl-3-tropanebutanol (XXXV), crystalline solid. XXXV (0.5 g.) dehydrated with 85% H2SO4, and the product reduced as described above gave 1-(2-pyridyl)-1-p-tolyl-4-(3-tropanyl)butane. II (9.2 g.) with MeLi gave dimethyl-3-tropanecarbinol, which was dehydrated by refluxing with AcOH and concentrated HCl, and the product hydrogenated over Raney Ni to give 3-isopropyltropane as an oil. XXII (11.3 g.) treated with C6H13Li gave 1,1-dihexyl-3-(N-isopropylnortropane)ethanol (XXXVI), white solid. XXXVI (8 g.) refluxed 45 min. with AcOH and HCl gave an unsatd. product as the HCl salt which was hydrogenated over Raney Ni to 2-hexyl-1-[3-(N-isopropylnortropanyl)]octane as an oil. XXXIII (14.3 g.) similarly treated with cyclopentylmagnesium bromide gave cyclopentyl 3-(3-tropanyl)propyl ketone (XXXVII), b0.9 152-6°. XXXVII (3.5 g.) dehydrated and the product reduced over Raney Ni gave 1-cyclopentyl-1-phenyl-4-(3-tropanyl)butane, a colorless oil.

IT 95131-86-5P, 3-Tropaneethanol, α,α-diphenyl-
102470-52-0P, 3-Tropaneethanol, α-phenyl-α-2-pyridyl-
102809-40-5P, 3-Nortropaneethanol, α,α-dihexyl-8-isopropyl- 102945-26-6P, 3-Tropaneethanol, α-cyclohexyl-α-phenyl- 103034-31-7P, 3-Tropaneethanol, α-(2-cyclohexylethyl)-α-phenyl- 108300-13-6P, 3-Tropaneethanol, α-ethyl-α-phenyl- 114277-51-9P, 3-Nortropaneethanol, 8-isopropyl-α-(p-methoxyphenyl)-α-phenyl-
RL: PREP (Preparation)
(preparation of)

RN 95131-86-5 CAPLUS
CN 3-Tropaneethanol, α,α-diphenyl- (6CI, 7CI) (CA INDEX NAME)



RN 102470-52-0 CAPLUS
CN 3-Tropaneethanol, α-phenyl-α-2-pyridyl- (6CI) (CA INDEX NAME)



RN 102809-40-5 CAPLUS
CN 3-Nortropaneethanol, α,α-dihexyl-8-isopropyl- (6CI) (CA INDEX NAME)



RN 102945-26-6 CAPLUS
CN 3-Tropaneethanol, α-cyclohexyl-α-phenyl- (6CI) (CA INDEX NAME)



RN 103034-31-7 CAPLUS
CN 3-Tropaneethanol, α-(2-cyclohexylethyl)-α-phenyl- (6CI) (CA INDEX NAME)



RN 108300-13-6 CAPLUS
CN 3-Tropaneethanol, α-ethyl-α-phenyl- (6CI) (CA INDEX NAME)



RN 114277-51-9 CAPLUS
CN 3-Nortropaneethanol, 8-isopropyl-α-(p-methoxyphenyl)-α-phenyl- (6CI) (CA INDEX NAME)



=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	61.26	234.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.58	-8.58

FILE 'STNGUIDE' ENTERED AT 09:09:28 ON 14 MAY 2007

```
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 11, 2007 (20070511/UP).

=> d his

     (FILE 'HOME' ENTERED AT 09:03:29 ON 14 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 09:03:39 ON 14 MAY 2007
L1             STRUCTURE UPLOADED
L2             STRUCTURE UPLOADED
L3           1 S L2
L4         211 S L2 FULL

     FILE 'CAPLUS' ENTERED AT 09:05:21 ON 14 MAY 2007
L5          11 S L4 FULL

     FILE 'STNGUIDE' ENTERED AT 09:09:28 ON 14 MAY 2007

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    0.30     234.77

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00      -8.58

STN INTERNATIONAL LOGOFF AT 09:12:17 ON 14 MAY 2007
```